

Extended Data Table 1


	Severe	Moderate	Mild	Asymptomatic	Negative	Total
n	55	103	7	29	30	224
Age (years)	63.15 ± 17.79	64.56 ± 15.77	35.14 ± 14.48	46.55 ± 19.82	37.23 ± 11.39	57.65 ± 19.37
Sex (M F)	30 (54%) 25 (46%); n=55	49 (48%) 54 (52%); n=103	0 (54%) 7 (100%); n=7	8 (36%%) 14 (64%); n=22	1 (3%) 29 (97%); n=30	88 (41%) 129 (59%); n=217
BMI	32.25 ± 8.8; n=50	30.48 ± 8.28; n=97		28.88 ± 8.1; n=18	-	30.84 ± 8.44; n=176
COVID Risk Factors						
None	13 (24%)	25 (24%)		-	-	38 (24%); n=158
Cancer (<1 year)	5 (9%)	6 (6%)		-	-	11 (7%); n=158
Chronic Heart Disease	15 (27%)	30 (29%)		-	-	45 (28%); n=158
Hypertension	28 (51%)	55 (53%)		-	-	83 (53%); n=158
Chronic Lung Disese	9 (16%)	25 (24%)		-	-	34 (22%); n=158
Immunosuppresion	4 (7%)	9 (9%)			-	13 (8%); n=158



Supplementary Figure 1. a, Violin plots of days from symptom onset (DFSO) in severe and moderate COVID-19 samples. DFSO data was not available for a limited number of samples from each group. Significance was determined using a two-sided Mann-Whitney U test. b, Violin plots of the number of reactivities in severe COVID-19, moderate COVID-19, mild or asymptomatic COVID-19, severe SLE, and APECED patient samples at different score cutoffs. SLE and APECED patients were screened as previously described (Wang et al, manuscript in preparation). Due to the smaller size of the yeast exoproteome library used to screen the SLE and APECED samples, reactivities in the COVID-19 cohort against proteins that were not in the previously described yeast exoproteome library were removed from these analyses. Significance was determined using a Kruskal-Wallis test followed by a Dunn's test. Significance indicators above the APECED group represent significance in comparison to all other groups. In all violin plots in this figure, solid lines represent the median and dotted lines represent the first or third quartile. **P ≤ 0.001, ****P ≤ 0.001.




Supplementary Figure 2. a, Percentage of reactivities (REAP score greater than score cutoff) in COVID-19 patients present within 10 days from symptom onset at various score cutoffs. **b,** Percentage of reactivities in COVID-19 patients that had a REAP score less than the score cutoff (using various score cutoffs) at the first time point sampled and an increase in REAP score of at least 1 at the last time point. **c,** Percentage of reactivities in COVID-19 patients that had a REAP score greater than the score cutoff (using various score cutoffs) at the first time point sampled and a decrease in REAP score of at least 1 at the last time point. **d-I,** Plots of longitudinal changes in REAP score for autoreactivities against IFNA13 (**d**), IL6 (**e**), CCL15 (**f**), IFNW1 (**g**), IL13 (**h**), CCR4 (**i**), TSLP (**j**), IL34 (**k**), and PTPRJ (**l**) in COVID-19 patients.



Supplementary Figure 3. a, Single point pan-IgG autoantibody ELISAs conducted 1:25 or 1:50 plasma dilution (indicated in graph titles). Dotted line represents the healthy donor average plus 3 standard deviations. The number of unique controls used in each ELISA is indicated below the control column in each graph. Technical replicates are depicted as distinct points on graphs. **b,** GM-CSF, **c,** CD38, and **d,** IL-18R β pan-IgG autoantibody ELISAs conducted with serial dilutions of COVID-19 patient or uninfected control plasma. Technical replicates were performed for all dilutions and samples. Error bars represent standard deviation. Results are averages of 2 technical replicates. Curves were fit using a sigmoidal 4 parameter logistic curve. **e,** CD38 and **f,** IL-18R β IgG subclass specific ELISAs conducted with 1:100 plasma dilution. Technical replicates are depicted as distinct points on graphs. Background optical density (OD) values were subtracted to normalize for varying background levels of the subclass specific secondary antibodies. All error bars in this figure represent standard deviation.

Log₁₀[Serum Dilution]



Supplementary Figure 4. a-t, Concentration of plasma CCL11 (a), CCL15 (b), CCL2 (c), CCL26 (d), CCL8 (e), CXCL1 (f), CXCL12 (g), CXCL13 (h), FLT3LG (i), IFNA2 (j), IL1A (k), IL1B (I), IL13 (m), IL16 (n) and IL21 (o), IL22 (p), IL6 (q), PDGFA (r), TGFA (s), and TSLP (t) measured by a Luminex assay in samples stratified by COVID-19 disease severity and REAP reactivity (AAb+; REAP score >= 2) against the corresponding cytokine. Significance was determined using two-sided, Wilcoxon rank-sum test; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. All error bars in this figure represent standard deviation.


Moderate (AAb)

Severe (AAb⁻)

Moderate/Severe (AAb⁺)

⊨ HCW

Sample group




Supplementary Figure 5. a-d, Percent B cells (a), NK cells (b), Activated CD4+ T cells (c), activated CD8+ T cells (d) among peripheral leukocytes in samples stratified by COVID-19 disease severity and REAP reactivity (score >= 2) to CD38. e, Representative flow plot of B cells (CD19+HLA-DR+) for a. f, Representative flow plot of activated CD8+ T cells (CD19+HLA-DR+) for d. g-j, Percent CD4+ T cells (g), CD8+ T cells (h), NKT cells (i), and NK cells (j) among peripheral leukocytes in samples stratified by COVID-19 disease severity and REAP reactivity (score >= 2) to CD3E. k, Representative flow plot of T cells (CD3+), NK cells (CD56+), and NKT cells (CD3+CD56+) for g-j.

Brilliant Violet BV605-CD3

Supplementary Figure 6 From live From live Brilliant Violet 711-CD19 Violet 711-CD19 10 800K CD19+HLA-DR 4.86 SSC-A 600k 600K 600K 10 aut 200k 200K Bri 200K 400K 600K 800K1.0M 400K 600K 800K1.0M 200K 400K 600K 800K1.0N 200K 400K 600K 800K1.0M FSC-A FSC-A SSC-A SSC-A Brilliant Violet 605-CD3 FITC-HLA-DR From CD3 CD19 CD56 From CD3-CD19-CD56-From CD3 CD19 CD56 From CD3 CD19 CD56 From CD3⁺ From CD3-CD19-CD66b CD14 CD16 CD66b CD14 CD16 CD304 CD66b CD14 CD16 CD304 CD66b Brilliant Violet 785-CD16 CD1c+HLA-DR 10⁵ CD141+HLA-DR+ 0.34 Texas Red-CD56 Texas Red-CD56 CD304 4.08 104 10⁴ 104 FITC-HLA-DR FITC-HLA-DR 10⁴ 10⁴ PE-CD304 10³ 10³ 10 0 . H . H 104 200K 400K 600K 800K1.0M -10³ 0 10³ 10⁴ AlexaFluor 700-CD141 10³ 103 104 103 Brilliant Violet 605-CD3 PerCP-Cy5.5-CD66b PE-Cy7-CD14 FSC-A AlexaFluor 647-CD1c From CD3+TCRb+ b 1.0M 1.0M AlexaFluor 647-CD19 10⁴ PerCP-Cy5.5-CD8 800K 800K 8001 Live/Dead Fixable 10 Single Cells 96.4 TCRbCD19- CD3TCRb+ 10 SSC-H 600k 600K 600K 10 10³ 400K 400K 400K 400K 600K 800K1.0M 200K 400K 600K 800K1.0M 200K 400K 600K 800K1.0M 104 10⁵10⁶ FSC-A SSC-A Brilliant Violet 785-CD45.2 Brilliant Violet 605-CD3&TCRb APC-Cy7-CD4 FSC-A From CD4⁻CD8a⁻ From CD3⁻TCRb⁻CD19⁻ From CD4 From CD8a⁺ From TCRgd* From NK1.1+ Brilliant Violet 785-CD45.2 CD44+CD69+ CD44+CD69+ 700-CD44 700-CD44 AlexaFluor 700-CD44 700-CD44 10⁵ 10 10⁵ CD44+CD69+ 50.4 104 10 PE-Cy7-TCRgd 10 10⁴ 10³ 10³ AlexaFluor AlexaFluor AlexaFluor 10 10 10 10 0 0 -10³ 104 10⁵10⁶ Brilliant Violet 605-CD3&TCRb Brilliant Violet 711-NK1.1 Pacific Blue-CD69 Pacific Blue-CD69 Pacific Blue-CD69 Pacific Blue-CD69 ive/Dead Fixable Agua Single Cells 79.1 Single Cells 94.8 Lymphocyte: 45.2 800K 800K 800K 800K 600F 600K 600K AlexFluor 400F 400K 400K 400K 200K 400K 600K 800K1 0M 400K 600K 800K1.0M 200K 400K 600K 800K1.0M 200K 400K 600K 800K1.0M Brilliant Violet 605-CD45 FSC-A FSC-A SSC-A SSC-A SSC-A From CD3⁻TCRb⁻NK1.1⁻CD19⁻ From Ly6G⁴ From CD64 From CD64 From Siglec-F-SSClow From Siglec-F-SSClov **Brilliant Violet 785-CD11b** CD3TCRbNK1.1CD19-37.5 CD11b-Ly6C- CD11+Ly6C+ 25.5 70.8 10 10 PerCP-Cy5.5-Ly6C PerCP-Cy5.5-Ly6C 8001 800k 10 10⁵ 600k 10 10 400F 10 400k 10⁵ 200K 400K 600K 800K1.0M 10³ PE-CD64 104 105 -10³ 0 10³ 10⁴ 10⁵ APC-Cy7-CD3TCRbNK1.1CD19 10⁴ PE-CD64 PerCP-Cy5.5-Ly6C SSC-A Brilliant Violet 711-Siglec F From NK1.1* 1.0M 1.0M Single Cells 96.6 Live/Dead Fixable Aqua 800K 800K 800K 8001 10 10 PE-CD27 SSC-H 600F 400K 400K 10 400K 400K 35.1 200K 400K 600K 800K1.0N 200K 400K 600K 800K1.0M 103 -10³ 0 10³ 10⁴ 10⁵ Brilliant Violet 605-NK1.1 Brilliant Violet 785-CD45.2 FSC-A FSC-A SSC-A AlexaFluor 700-CD11b From NK1.1+ From CD45.2+ From CD3⁺TCRb⁺ From CD8a From CD4⁺ Brilliant Violet 605-NK1.1 1.0M 10⁵ Violet 711-CD44 10 CD44+KLRG1+ Brilliant Violet 711-CD44 10 CD44+KLRG1+ CD4 10⁵ 800K 10⁴ APC-CD4 CD3TCRb+ 600K 42.2 10 10 Brilliant 0 103 104 10⁵ 104 104 104 10⁵ 104 10 10 10 FITC-KLRG1 APC-Cy7-CD3&TCRb PerCP-Cy5.5-CD8a FITC-KLRG1 FITC-KLRG1

Supplementary Figure 6. a, Gating strategy to identify B cells in Fig. 2f, monocytes in **Fig. 2h-k**, T cells, NKT cells, and NK cells in **Supplementary Fig. 5.** in human PBMCs. **b,** Gating strategy to identify CD11b+Ly6Chigh monocytes and Ly6C+CD11b+CD64+ macrophages in mouse lung tissues described in **Fig. 3c-e. c,** Gating strategy to identify CD44+CD69+ lymphocytes in mouse lung tissues described in **Fig. 3f-g. d,** Gating strategy to identify KLRG1+ and CD11b+ NK cells described in **Fig. 3k-l.**



Supplementary Figure 7. Correlation of normalized GRM5 REAP scores with Glasgow Coma Scale scores in severe COVID-19 samples. Blue line shows a linear regression fit. Samples from the same patient were indicated with the same color points.